Brief: PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001
19/08/2024 13:11
Aug 19 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER’S SAIRIYO THERAPEUTICS RECEIVES APPROVAL TO
INITIATE
A PHASE 1 HUMAN CLINICAL TRIAL OF PD-001 (REFORMULATED
CEPHARANTHINE)
Source text for Eikon: ID:nGNXbCV5nz
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application